Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma

Documenti analoghi

• A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid For Patients With Glioblastoma
  di: Krauze, Andra V., et al.
  Pubblicazione: (2015)
• AT-33 A PHASE II STUDY OF CONCURRENT RADIATION THERAPY, TEMOZOLOMIDE AND THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID FOR PATIENTS WITH GLIOBLASTOMA MULTIFORME
  di: Krauze, Andra V., et al.
  Pubblicazione: (2014)
• Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma
  di: Mathen, Peter, et al.
  Pubblicazione: (2020)
• ACTR-57. DOES THE ADDITION OF VALPROIC ACID TO CONCURRENT RADIATION THERAPY AND TEMOZOLOMIDE IMPROVE PATIENT OUTCOME? – CORRELATIVE ANALYSIS OF RTOG 0525, SEER AND A PHASE II NCI TRIAL
  di: Krauze, Andra, et al.
  Pubblicazione: (2017)
• RTHP-15. INCIDENCE OF MASTOID EFFUSION IN PATIENTS RECEIVING PHOTON RADIATION THERAPY FOR GLIOBLASTOMA
  di: Rowe, Lindsay, et al.
  Pubblicazione: (2017)